All In Biotech

Drug Trial Radar · NCT00450216

Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment

A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment

Last checked: Nov 19, 2026Latest source record: Dec 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 906 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

906

Actual

Start

Mar 2007

Primary completion

Aug 2008

Study completion Oct 2008

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Mar 22, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate whether HZT-501 is effective in reducing the rate of development of ibuprofen-associated ulcers in patients who require long-term daily use of ibuprofen.

Conditions

  • Ulcer

Interventions

  • Ibuprofen/famotidineDrug

    HZT-501: Ibuprofen800mg/famotidine 26.6mg administered orally 3 times daily for 24 weeks

  • IbuprofenDrug

    Ibuprofen 800mg administered orally 3 times daily for 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Develop Endoscopically-diagnosed Gastric UlcersTime frame: 24 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.